Azithro my one dose nd use
Reading File
Finding Sources
Finding Sources
Finding Sources
Here's a concise summary of Azithromycin single-dose uses:
Azithromycin — Single-Dose Regimens & Indications
1. Chlamydia trachomatis (Urogenital — non-LGV)
- 1 g orally as a single dose
- First-line alternative to doxycycline (doxycycline preferred for urogenital and especially rectal chlamydia due to ~5% higher cure rate)
- Preferred for pregnant women due to its safety profile
- Single-dose advantage: better adherence — Goldman-Cecil Medicine
2. Gonorrhea (Neisseria gonorrhoeae)
- Used in combination, not alone
- Ceftriaxone 250–500 mg IM + Azithromycin 1 g PO (single dose) — to cover possible co-infection with chlamydia
- Smith & Tanagho's Urology; Berek & Novak's Gynecology
3. Cholera (Vibrio cholerae)
- Adults: 1 g single dose
- Children: 20 mg/kg single dose
- Red Book 2021
4. Traveler's Diarrhea
- 1000 mg single dose (or 500 mg daily × 3 days if single dose fails)
- Empirical treatment, especially in fluoroquinolone-resistant regions
- Goldman-Cecil Medicine
5. Trachoma
- Single dose (topical + systemic) — Sherris & Ryan's Medical Microbiology
Key Points
| Feature | Detail |
|---|---|
| Drug class | Macrolide antibiotic |
| Mechanism | Inhibits bacterial protein synthesis (50S ribosomal subunit) |
| Single-dose benefit | Improves compliance/adherence |
| Avoid in | Rectal chlamydia (lower efficacy vs doxycycline) |
| Safe in pregnancy | Yes — preferred over doxycycline |
Summary: The most classic single-dose azithromycin use is 1 g PO for urogenital chlamydia and combined with ceftriaxone for gonorrhea. It's also used as a single dose for cholera and traveler's diarrhea.
Azithromycine
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive overview of Azithromycin:
Azithromycin — Complete Drug Profile
Class & Structure
- Class: Macrolide antibiotic (azalide subclass)
- Structure: 15-atom lactone ring (vs 14-atom in erythromycin) with a methylated nitrogen inserted into the ring
- Brand names: Zithromax, Z-PAK, TRI-PAK, AzaSite (ophthalmic)
Mechanism of Action
Binds irreversibly to the 50S ribosomal subunit → inhibits bacterial protein synthesis → bacteriostatic
Spectrum of Activity
| Coverage | Organisms |
|---|---|
| Gram-positive | Streptococcus spp., Staphylococcus spp. (slightly less than erythromycin) |
| Gram-negative | H. influenzae (slightly more active than erythromycin), Moraxella, Legionella |
| Atypicals | Chlamydia spp. (highly active), Mycoplasma, Ureaplasma |
| Mycobacteria | M. avium complex (MAC) |
| Other | Bordetella pertussis, Vibrio cholerae, T. gondii |
Pharmacokinetics (Key Features)
| Property | Detail |
|---|---|
| Administration | Oral or IV |
| Oral absorption | Rapid, well-tolerated |
| Serum level | Low (~0.4 mcg/mL after 500 mg) |
| Tissue penetration | Extremely high — 10–100× serum levels in tissues and phagocytes (except CSF) |
| Half-life (tissue) | 2–4 days → allows short-course and once-daily dosing |
| Elimination half-life | ~3 days |
| Food effect | Tablets/suspension: with or without food; extended-release: empty stomach |
| Antacids | Al/Mg antacids delay absorption but don't reduce overall bioavailability |
| Drug interactions | Minimal — does NOT inhibit CYP450 (unlike erythromycin/clarithromycin) |
Clinical Uses & Dosing
Adults
| Indication | Dose |
|---|---|
| Pharyngitis / tonsillitis / skin & soft tissue | 500 mg day 1, then 250 mg/day × 4 days (Z-PAK) |
| Community-acquired pneumonia (outpatient) | 500 mg day 1, then 250 mg/day × 4 days |
| CAP (inpatient) | 500 mg IV/day × 3 days → 500 mg PO to complete 7–10 days |
| Acute sinusitis | 500 mg PO once daily × 3 days |
| COPD exacerbation | Z-PAK OR 500 mg/day × 3 days |
| Chlamydial cervicitis/urethritis | 1 g PO single dose |
| Gonorrhea | 2 g PO single dose (less common now) |
| Acute PID | 500 mg IV × 1–2 days → 250 mg PO to complete 7 days |
| MAC prophylaxis (HIV) | 1200 mg PO once weekly |
| MAC treatment (HIV) | 500–600 mg PO daily + ethambutol ± rifabutin |
| Endocarditis prophylaxis | 500 mg PO × 1 (30–60 min before procedure) |
| Cystic fibrosis (anti-inflammatory) | 500 mg PO 3× per week (Mon/Wed/Fri) |
| Cholera | 1 g PO single dose |
| Traveler's diarrhea | 1 g PO single dose |
| Ophthalmic (AzaSite) | 1 drop BID × 2 days, then once daily × 5 days |
Children (key doses)
| Indication | Dose |
|---|---|
| CAP (mild, ≥3 mo) | 10 mg/kg day 1 (max 500 mg), then 5 mg/kg/day × 4 days |
| Pharyngitis / tonsillitis | 12 mg/kg/day × 5 days (max 500 mg/day) |
| Sinusitis (≥6 mo) | 10 mg/kg/day × 3 days (max 500 mg) |
| Pertussis (≥6 mo) | 10 mg/kg × 1, then 5 mg/kg/day × 4 days |
| Endocarditis prophylaxis | 15 mg/kg PO × 1 (max 500 mg) |
Adverse Effects
| Effect | Notes |
|---|---|
| QT prolongation | Risk of torsades de pointes — caution with hypokalemia, hypomagnesemia, bradycardia, other QT-prolonging drugs |
| GI (nausea, vomiting, diarrhea) | Less than erythromycin |
| Hepatotoxicity | Elevated liver enzymes, cholestatic jaundice |
| SJS/TEN | Rare serious skin reactions |
| Infantile hypertrophic pyloric stenosis | Reported in young infants |
| Myasthenia gravis exacerbation | Known association |
| Pain at IV site | With IV use; never give as bolus or IM |
Contraindications & Cautions
- Contraindicated: Hypersensitivity to macrolides; history of cholestatic jaundice with prior azithromycin use
- Use with caution: Hepatic impairment, GFR <10 mL/min, prolonged QT, arrhythmias
- Drug interaction: Nelfinavir can increase azithromycin levels → monitor LFTs and hearing
- Not recommended for otitis media (increased resistant pathogens)
- Poor CNS penetration
Advantage Over Erythromycin & Clarithromycin
- Longer tissue half-life → shorter courses / single-dose regimens possible
- No CYP450 inhibition → far fewer drug interactions
- Better gram-negative coverage
- Better GI tolerability
Sources: Katzung's Basic & Clinical Pharmacology 16th Ed. | Harriet Lane Handbook 23rd Ed.
Metronidazole
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Here is the complete drug profile for Metronidazole:
Metronidazole — Complete Drug Profile
Class & Structure
- Class: Nitroimidazole — antibiotic + antiprotozoal
- Brand names: Flagyl, MetroGel, MetroCream, MetroLotion, Vandazole, Nuvessa, Rosadan
Mechanism of Action
- Selectively absorbed by anaerobic bacteria and sensitive protozoa
- Inside anaerobic cells, the nitro group acts as an electron acceptor → reacts with reduced ferredoxin
- Produces cytotoxic free radicals that bind to DNA and proteins → DNA strand breakage → cell death
- This reduction happens only in anaerobic cells → minimal effect on human cells or aerobic bacteria
Drug is selectively toxic to anaerobes — aerobic bacteria are unaffected
Spectrum of Activity
| Type | Organisms |
|---|---|
| Anaerobic bacteria | Bacteroides fragilis, Clostridioides difficile, Fusobacterium, Prevotella |
| Protozoa | Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis |
| Other bacteria | Helicobacter pylori (in combination) |
| ❌ No activity | Aerobic or facultative bacteria |
Pharmacokinetics
| Property | Detail |
|---|---|
| Oral absorption | Complete and rapid |
| Distribution | Wide — tissues, fluids, CSF, vaginal fluid, saliva, breast milk |
| CSF penetration | Excellent — reaches levels similar to serum |
| Metabolism | Hepatic (side-chain oxidation + glucuronidation) — accumulates in hepatic failure |
| Excretion | Urine (parent drug + metabolites) |
| Route | Oral, IV, vaginal gel, topical cream/gel |
Clinical Uses & Dosing
Adults
| Indication | Dose |
|---|---|
| Amebiasis | 500–750 mg PO Q8h × 10 days |
| Anaerobic infections | 30 mg/kg/day PO/IV ÷ Q6–8h (max 4 g/day); IV loading: 15 mg/kg over 1 hr |
| Bacterial vaginosis | 500 mg PO BID × 7 days; OR vaginal gel 0.75% QHS × 5 days; OR 1.3% vaginal gel × 1 dose |
| Trichomoniasis | 2 g PO single dose OR 500 mg PO BID × 7 days (treat sexual contacts) |
| Giardiasis | 250 mg PO TID × 5 days |
| C. difficile | 500 mg TID PO/IV × 10–14 days (fulminant: IV + oral vancomycin) |
| H. pylori (combo) | 250–500 mg TID–QID × 10–14 days (with amoxicillin + PPI ± clarithromycin) |
| Brain abscess | IV metronidazole (covers anaerobes) |
| Intra-abdominal/pelvic infections | Combined with aerobic coverage |
| Rosacea (topical) | 0.75% cream BID or 1% cream once daily |
Children
| Indication | Dose |
|---|---|
| Amebiasis | 35–50 mg/kg/day ÷ Q8h × 10 days (max 750 mg/dose) |
| Anaerobic infection | PO: 30–50 mg/kg/day ÷ Q8h; IV: 22.5–40 mg/kg/day ÷ Q6–8h |
| Giardiasis | 15–30 mg/kg/day ÷ TID × 5–7 days |
| Trichomoniasis (<45 kg) | 45 mg/kg/day ÷ TID × 7 days |
Adverse Effects
| Effect | Notes |
|---|---|
| GI | Nausea, vomiting, diarrhea, epigastric distress (most common) |
| Metallic taste | Very characteristic |
| Disulfiram-like reaction | With alcohol — avoid alcohol for 24–48 hr after dose |
| Peripheral neuropathy | With prolonged use (may need to stop drug) |
| Neurotoxicity | Dizziness, vertigo, paresthesia |
| QT prolongation | Caution with other QT-prolonging drugs |
| Candidiasis | May worsen (oral/vaginal yeast overgrowth) |
| Leukopenia | Rare |
| Urine discoloration | Dark/reddish-brown |
| SJS | Rare |
Contraindications & Cautions
- Contraindicated: Cockayne syndrome (fatal liver failure reported); first trimester pregnancy
- Caution: CNS disease, blood dyscrasias, severe hepatic impairment (reduce dose 50% in Child-Pugh C), GFR <10 mL/min
- Breastfeeding: If 2 g single dose used, discontinue breastfeeding for 12–24 hr
Drug Interactions
| Drug | Effect |
|---|---|
| Alcohol | Disulfiram-like reaction |
| Warfarin | ↑ anticoagulant effect (INR) |
| Phenytoin / Lithium | ↑ levels and toxicity |
| Phenobarbital / Rifampin | ↑ metronidazole metabolism → ↓ efficacy |
| QT-prolonging drugs | Additive QT prolongation |
Key Points to Remember
- Only drug with good coverage of both anaerobes AND protozoa
- Excellent CNS/CSF penetration → drug of choice for brain abscess (anaerobic)
- Single 2 g dose for trichomoniasis
- No longer single-agent first-line for C. diff (use vancomycin or fidaxomicin); still used IV in fulminant C. diff combined with oral vancomycin
- Single-dose oral NOT recommended for bacterial vaginosis — poor efficacy
Sources: Katzung's Basic & Clinical Pharmacology 16th Ed. | Harriet Lane Handbook 23rd Ed. | Lippincott Illustrated Reviews Pharmacology
This is a shared conversation. Sign in to Orris to start your own chat.